Groupama Asset Managment lowered its holdings in Insulet Co. (NASDAQ:PODD - Free Report) by 0.3% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,050,517 shares of the medical instruments supplier's stock after selling 2,888 shares during the period. Groupama Asset Managment owned approximately 1.50% of Insulet worth $2,445,000 at the end of the most recent reporting period.
Other large investors have also recently added to or reduced their stakes in the company. Blue Trust Inc. lifted its stake in Insulet by 84.1% during the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier's stock worth $30,000 after purchasing an additional 58 shares during the last quarter. Venturi Wealth Management LLC lifted its holdings in shares of Insulet by 633.3% in the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier's stock valued at $36,000 after purchasing an additional 133 shares during the last quarter. International Assets Investment Management LLC purchased a new stake in Insulet in the second quarter valued at approximately $32,000. UMB Bank n.a. boosted its holdings in shares of Insulet by 81.0% in the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier's stock valued at $37,000 after acquiring an additional 81 shares during the period. Finally, 1620 Investment Advisors Inc. purchased a new position in shares of Insulet during the second quarter worth approximately $52,000.
Insulet Stock Performance
Shares of Insulet stock traded down $2.12 during trading on Monday, hitting $265.47. 443,137 shares of the stock were exchanged, compared to its average volume of 545,836. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $279.40. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The stock has a market cap of $18.62 billion, a PE ratio of 45.46, a P/E/G ratio of 4.06 and a beta of 1.21. The stock's fifty day moving average is $247.48 and its 200 day moving average is $217.32.
Wall Street Analysts Forecast Growth
A number of analysts have weighed in on the company. Citigroup increased their price objective on Insulet from $250.00 to $275.00 and gave the stock a "buy" rating in a research report on Tuesday, October 1st. Morgan Stanley raised their price objective on Insulet from $234.00 to $317.00 and gave the stock an "overweight" rating in a report on Monday, November 11th. Piper Sandler upped their price target on Insulet from $230.00 to $285.00 and gave the stock an "overweight" rating in a research note on Tuesday, September 17th. BTIG Research lifted their target price on shares of Insulet from $260.00 to $270.00 and gave the company a "buy" rating in a report on Friday, November 8th. Finally, Raymond James increased their price objective on shares of Insulet from $213.00 to $260.00 and gave the company an "outperform" rating in a research report on Monday, October 14th. Three equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $255.60.
Check Out Our Latest Stock Report on PODD
About Insulet
(
Free Report)
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.
Featured Articles
Before you consider Insulet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insulet wasn't on the list.
While Insulet currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
